OncoMatch/Clinical Trials/NCT06342466
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Is NCT06342466 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Bortezomib and Pomalidomide for systemic amyloidosis.
Treatment: Bortezomib · Pomalidomide · Dexamethasone — This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.0 x 10^9/l, hemoglobin ≥70 g/l, platelets ≥50 x 10^9/l
Kidney function
egfr ≥20 ml/min/ 1.73 m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify